Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

for the Liver Cancer Study Group of Japan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.

Original languageEnglish
Pages (from-to)3-9
Number of pages7
JournalHepatology Research
Volume46
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1
Externally publishedYes

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Japan
Therapeutics
Necrosis
Clinical Trials
Molecular Targeted Therapy
Neoplasms
Liver

Keywords

  • Hepatocellular carcinoma
  • Liver Cancer Study Group of Japan
  • Modified Response Evaluation Criteria in Solid Tumors
  • Response Evaluation Criteria in Cancer of the Liver
  • Response Evaluation Criteria in Solid Tumors

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). / for the Liver Cancer Study Group of Japan.

In: Hepatology Research, Vol. 46, No. 1, 01.01.2016, p. 3-9.

Research output: Contribution to journalArticle

for the Liver Cancer Study Group of Japan. / Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). In: Hepatology Research. 2016 ; Vol. 46, No. 1. pp. 3-9.
@article{4e4bdc72df904e5c943613ac02ca36ae,
title = "Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)",
abstract = "The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50{\%} tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.",
keywords = "Hepatocellular carcinoma, Liver Cancer Study Group of Japan, Modified Response Evaluation Criteria in Solid Tumors, Response Evaluation Criteria in Cancer of the Liver, Response Evaluation Criteria in Solid Tumors",
author = "{for the Liver Cancer Study Group of Japan} and Masatoshi Kudo and Kazuomi Ueshima and Shoji Kubo and Michiie Sakamoto and Masatoshi Tanaka and Iwao Ikai and Junji Furuse and Takamichi Murakami and Masumi Kadoya and Norihiro Kokudo",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/hepr.12542",
language = "English",
volume = "46",
pages = "3--9",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

AU - for the Liver Cancer Study Group of Japan

AU - Kudo, Masatoshi

AU - Ueshima, Kazuomi

AU - Kubo, Shoji

AU - Sakamoto, Michiie

AU - Tanaka, Masatoshi

AU - Ikai, Iwao

AU - Furuse, Junji

AU - Murakami, Takamichi

AU - Kadoya, Masumi

AU - Kokudo, Norihiro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.

AB - The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.

KW - Hepatocellular carcinoma

KW - Liver Cancer Study Group of Japan

KW - Modified Response Evaluation Criteria in Solid Tumors

KW - Response Evaluation Criteria in Cancer of the Liver

KW - Response Evaluation Criteria in Solid Tumors

UR - http://www.scopus.com/inward/record.url?scp=84959339484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959339484&partnerID=8YFLogxK

U2 - 10.1111/hepr.12542

DO - 10.1111/hepr.12542

M3 - Article

AN - SCOPUS:84959339484

VL - 46

SP - 3

EP - 9

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 1

ER -